Subsequently, we measured CERS6 protein levels in ESCC patient-derived xenografts (PDX) models to evaluate the effect of ASO-CERS6 treatment in vivo (Fig. 6K). The gene discussed is CERS6; the disease is esophageal squamous cell carcinoma.